Preview

Медицинский Совет

Расширенный поиск

АДЪЮВАНТНАЯ ГОРМОНОТЕРАПИЯ ПРЕМЕНОПАУЗАЛЬНЫХ ЖЕНЩИН С ER+-РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

https://doi.org/10.21518/2079-701X-2017-6-156-159

Полный текст:

Аннотация

Адъювантная эндокринотерапия пременопаузальных пациентов с ER+-раком молочной железы обычно заключается в получении тамоксифена в течение 5 лет. Однако в случаях высокого риска рецидива заболевания возникает необходимость в подавлении (супрессии) функции яичников как основных генераторов эстрогенов, стимулирующих рост и прогрессирование заболевания, обычно с помощью агонистов гонадотропин-рилизинг-гормона. В результате наступившей медикаментозной постменопаузы становится возможным вместе с агонистами ГнРГ использовать не только тамоксифен, но и ингибиторы ароматазы, обладающие большей противоопухолевой активностью.

Об авторах

В. Ф. СЕМИГЛАЗОВ
Научно-исследовательский институт онкологии им. Н.Н. Петрова Минздрава России
Россия
д.м.н., профессор


В. В. СЕМИГЛАЗОВ
Первый Санкт-Петербургский государственный университет им. акад. И.П. Павлова
Россия
д.м.н.


В. Ю. ЛИФАНОВА
Научно-исследовательский институт онкологии им. Н.Н. Петрова Минздрава России
Россия


Список литературы

1. Семиглазов В.Ф., Палтуев Р.М., Манихас А.Г. Клинические рекомендации РООМ по диагностике и лечению рака молочной железы. АБВ-пресс, 2015. 501 с.

2. Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы: биология, местное и системное лечение. М.: СИМК, 2014. 352с.

3. Azim HA Jr, Michiels S, Bedard PL et at. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling, din. Cancer Res, 2012, 18: 1341-51.

4. Basser RL, O’Neill A, Martinelli G, et al: Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol, 2006, 24: 370-378.

5. Bellet M, Gray KP, Francis PA, et al: Twelvemonth estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT- EST substudy. J Clin Oncol, 2015, 34(4): 1584-1593.

6. Bernhard J, Luo W, Ribi K et al. Patirnt reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptorpositive (HR+) early breast cancer (BC). J Clin Oncol, 2015, 32(Suppl 15): Abstr. 557.

7. Coates AS, Winer ЕР, Goldhirsch A, et al: Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015, 2: 1533-1546.

8. Colleoni M, Anders C, The biology of breast cancer in young women is unique. The Oncologist, 2013, 15: 344-345.

9. Davidson N. Endocrine therapy for premenopausal women: type and duration. The Breast, 2015, 24(Suppl 1): PG11.01.

10. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 2013, 381: 805-816.

11. Dowsett M, Lonning PE, Davidson NE. Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. J Clin Oncol, 2016, 34: 1580-1583.

12. Dowsett M, Jacobs S, Aherne J et al. Clinical and endocrine effects of leuprorelin acetate in preand postmenopausal patients with advanced breast cancer. J Clin Oncol, 2016, 34: 1580-1583.

13. Francis PA, Regan MM, Fleming GF et al. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med, 2015, 372: 436-446.

14. Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifene versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the ABCG12 Trial 12. Ann Oncol, 2015, 26: 313-20.

15. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol, 1990, 1: 183-188.

16. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 2009, 20: 1319-1329.

17. Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res, 1985, 45: 4454-4459.

18. Moor HCF, Unger JM, Phillips KA et al. Gose relin for Ovarian Protection during Breast- Cancer Adjuvant Chemotherapy. N Engl J Med, 2015, 372.

19. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem highdose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet, 2005, 366: 1935-1944.

20. Pagani O, O’Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer, 1998, 34: 632-640.

21. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med, 2014, 371: 107-118.

22. Patridge A, Hughes M, Warner E et al. Subtypedependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol, 2016, 34: 3308-3314.

23. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of longterm outcome among 100,000 women in 123 randomised trials. Lancet, 2012, 379: 432-444.

24. Petrek JA, Naughton MJ, Case LD, et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol, 2006, 24: 1045-1051.

25. Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patientreported outcome in the SOFT trial. J Clin Oncol, 2016, 34: 1601-1610.

26. Rodriguez-Wallberg KA. Principles of cancer treatment: Impact on reproduction. Adv Exp Med Biol, 2012, 732: 1-8.

27. Tevaarwerk AJ, Wang M, Zhao F et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor positive breast cancer (E-3193, INT – 0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 2014, 32: 3948-3958.


Просмотров: 148


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)